Four products. One canonical layer.

Oushvaa Procure is the workflow application at the customer-facing edge of the platform. Hospital pharmacy heads create tenders. Vendors submit bids. AI scores each bid on price, reliability, compliance, and delivery SLA — with explainable reasoning the procurement committee can audit. Every transaction is canonical: vendors map to the same identity graph that the IQ rails use, so audit trails span beyond the tender itself.

It's not a tender notice board. It's a procurement operating system — RFQ, evaluation, award, PO, GRN, invoice, payment — running on top of the canonical company graph.

Key capabilities

• AI bid scoring with explainable reasoning, audit-ready for procurement committees
• NABH compliance mode enforcing min-3-quote rule, L1 vendor preference, drug-license validity at award
• Demand forecasting based on consumption history per hospital, with predictive reorder alerts
• Vendor intelligence layer with verified supplier profiles, drug license status, past performance scores
• Real-time price benchmarking against canonical drug pricing data from DrugIQ
• Compliance + audit trail with every procurement action logged for downstream review

DrugIQ is the pharmaceutical drug intelligence rail. India-deep at the core: 578,887 canonical drugs reconciled at salt level, NPPA ceiling integration, CDSCO regulatory cross-reference. Built on a salt-canonical foundation — clinical depth ingested at the molecule level fans out to every brand on the catalogue via deductive substitution.

Global expansion is in flight: openFDA, EMA SmPC, and Health Canada DPD adapters bring drug data from the major Western regulators into the same canonical layer. The cross-reference is what no competitor can match — Lexicomp doesn't have Indian depth; CIMS doesn't have global coverage; both treat their drug catalogues as proprietary islands.

Coverage tiers (à la carte)

Key capabilities

• Salt-canonical reference — 1,704 active ingredients, 578K canonical brands, 105K substitution pairs
• NPPA price tracking with daily MRP refresh and real-time ceiling-violation alerts
• CDSCO cross-reference for drug license status and regulatory pathway tracking
• PGx integration (CPIC, DPWG) calibrated for Indian sub-population genotype frequencies
• Adverse event signals with FAERS PRR/ROR/IC scoring per WHO-UMC methodology

MedevIQ is the global medical device intelligence rail. FDA MAUDE (19.7M records), EUDAMED (1.74M devices), Health Canada (296K), CDSCO (161K), TGA, PMDA, Swissmedic, MHRA, FDA Establishments — nine regulators integrated, cross-linked through the same canonical manufacturer pool.

The differentiator is the cross-jurisdictional manufacturer graph. 64,892 canonical manufacturers tagged with country and parent-child corporate relationships. Stryker Australia rolls up to Stryker Corporation; every subsidiary worldwide is linked. ECRI doesn't do this. GlobalData doesn't do this. Indian-market vendors don't have global rollup; global vendors don't have CDSCO depth. MedevIQ is the only platform that sits in both.

Coverage tiers (à la carte)

Key capabilities

• Cross-regulator device search — one device, all 9 regulator records, in one canonical query
• Adverse event scoring across 19.7M FDA MAUDE rows with structured product-code, manufacturer, event-type queryability
• Manufacturer hierarchy with 3,385 parent-child relationships across 50+ jurisdictions
• FDA establishment supply chain at FEI granularity — who makes it, where, under what GMP inspection status
• Recall + safety alert cross-reference across FDA recalls, Canada Vigilance, MHRA alerts, EUDAMED certificates

BiologicsIQ is the biologics and cell/gene therapy rail. 111 editorial-tier products spanning monoclonal antibodies, antibody-drug conjugates, bispecifics, CAR-T (autologous + allogeneic), AAV gene therapies, lentiviral, CRISPR ex vivo, recombinant proteins, Fc fusions, peptides, biosimilars, and anti-amyloid biologics.

The differentiator vs Cortellis and Citeline is two-fold: cross-product canonical identity (a biologic sponsor links to the same canonical company that DrugIQ + MedevIQ use), and FDA establishment-level CDMO supply chain at FEI granularity. Every approved biologic linked to its manufacturing site with GMP classification, inspection history, and cross-sponsor concentration risk visible.

Coverage tiers (à la carte)

Key capabilities

• Editorial Tier-A monographs with regulator pathway, designations, indications, approvals across multiple jurisdictions
• FDA establishment supply chain — every biologic linked to its manufacturing site at FEI granularity
• CDMO concentration analysis — top 18 CDMOs canonicalized including Lonza, Samsung Biologics, WuXi, Catalent
• Cross-product canonical identity — a biologic sponsor maps to the same entity as in DrugIQ + MedevIQ
• Modular regulator entitlements — buy the markets you actually sell into, not the ones you don't